Recombinant humanized monoclonal IgG1 antibody directed against vascular endothelial growth factor (VEGF). Prepn: L. G. Presta et al., Cancer Res. 57, 4593 (1997); M. Baca et al., WO 9845331 (1998 to Genentech). Biodistribution study: Y. S. Lin et al., J. Pharmacol. Exp. Ther. 288, 371 (1999). Clinical pharmacokinetics: M. S. Gordon et al., J. Clin. Oncol. 19, 843 (2001). Clinical trial in renal cancer: J. C. Yang et al., N. Engl. J. Med. 349, 427 (2003); in combination therapy in colorectal cancer: F. Kabbinavar et al., J. Clin. Oncol. 21, 60 (2003). Symposium on antiangiogenic and antitumor activity: Semin. Oncol. 29, Suppl. 16, 1-18 (2002). Review of development and clinical experience: N. Ferrara et al., Nat. Rev. Drug Discovery 3, 391-400 (2004); of clinical efficacy and safety: R. E. Sanborn, A. B. Sandler, Expert Opin. Drug Saf. 5, 289-301 (2006).
Antineoplastic.
Antineoplastic; Monoclonal Antibodies